Published in Cor Vasa on January 01, 1991
[Intensive vitamin D supplementation in the treatment of osteoporosis]. Vnitr Lek (2004) 1.41
Pharmacokinetics of acetylsalicylic acid and its metabolites at low doses: a compartmental modeling. Methods Find Exp Clin Pharmacol (1995) 0.98
Circulating advanced glycation end product levels in rats rapidly increase with acute renal failure. Kidney Int Suppl (2001) 0.87
Insulin resistance and vitamin D deficiency in patients with chronic kidney disease stage 2-3. Physiol Res (2010) 0.84
Hippurate participates in the correction of metabolic acidosis. Kidney Int Suppl (2001) 0.82
Acute effect of hydrochlorothiazide on renal calcium and magnesium handling in postmenopausal women. Physiol Res (1999) 0.82
Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension. J Cardiovasc Pharmacol (1994) 0.82
The prevalence of insulin resistance in kidney disease patients before the development of renal failure. Nephron (1995) 0.82
Inhibitor(s) of protein synthesis in uremic serum and urine: partial purification and relationship to amino acid transport. Biochem Med (1982) 0.82
Comparative experimental study of immunogenicity of the Czechoslovak and Soviet strain of M. Bovis (BCG). Czech Med (1984) 0.81
Participation of P-dependent and P-independent glutaminases in rat kidney ammoniagenesis and their modulation by metabolic acidosis, hippurate and insulin. Physiol Res (1998) 0.80
Cytodiagnostic study of women with primary amenorrhoea and karyotype 46XX. Acta Cytol (1977) 0.80
Analytical identity of an inhibitor of sodium transport isolated from human serum and urine. Nephron (1985) 0.80
DNA damage of lymphocytes in experimental chronic renal failure: beneficial effects of losartan. Kidney Int Suppl (2001) 0.80
46, XX gonadal dysgenesis and ovarian hypoplasia. Humangenetik (1974) 0.80
Plasma tryptophan level in chronic renal failure. Clin Nephrol (1980) 0.79
Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. J Hum Hypertens (2003) 0.79
Dicentric Yp chromosome in a patient with the gonadal dysgenesis and gonadoblastoma. Humangenetik (1975) 0.79
Oxidative stress and plasma concentrations of coenzyme Q10, alpha-tocopherol, and beta-carotene in patients with a mild to moderate decrease of kidney function. Nephron (2001) 0.79
Does magnesium dysbalance participate in the development of insulin resistance in early stages of renal disease? Physiol Res (2002) 0.78
Chromosomal changes in rat pituitary and bone marrow induced by long-term estogen administration. Neoplasma (1977) 0.78
The densitometric study of G bands on human metaphase chromosomes. Humangenetik (1973) 0.78
A highly sensitive HPLC method for the simultaneous determination of acetylsalicylic, salicylic and salicyluric acids in biologic fluids: pharmacokinetic, metabolic and monitoring implications. Methods Find Exp Clin Pharmacol (1996) 0.78
[Effect of hormone replacement therapy on the cardiovascular system]. Ceska Gynekol (2002) 0.77
Inhibition of glucose utilization in isolated rat soleus muscle by pseudouridine: implications for renal failure. Nephron (1993) 0.77
A procedure for the isolation of an inhibitor of sodium transport from the urine of uraemic patients. Physiol Bohemoslov (1982) 0.77
The role of magnesium deficiency in insulin resistance: an in vitro study. J Hypertens Suppl (1991) 0.77
Isolation of mycobacterial phage from the laboratory strain Mycobacterium leprae murium "Douglas". Czech Med (1984) 0.77
Pathogenesis and consequences of the alteration of glucose metabolism in renal insufficiency. Adv Exp Med Biol (1987) 0.76
Pseudouridine excretion in healthy subjects and its accumulation in renal failure. Nephron (1992) 0.76
Enalapril in subantihypertensive dosage attenuates kidney proliferation and functional recovery in normotensive ablation nephropathy of the rat. Physiol Res (1999) 0.76
Magnesium deficiency impairs rat soleus muscle glucose utilization and insulin sensitivity. Mater Med Pol (1993) 0.76
Accumulated end products participate in glucose intolerance and insulin resistance in uremia. Nephron (1993) 0.75
[Effect of coenzyme Q10 in patients with kidney diseases]. Cas Lek Cesk (2001) 0.75
[Renal clearance of hippurate in persons with chronic renal insufficiency]. Vnitr Lek (1994) 0.75
[Pharmacokinetic modeling in clinical practice: pefloxacin]. Bratisl Lek Listy (1990) 0.75
The synthesis of middle molecular substances in rat tissues: in vitro study. Proc Eur Dial Transplant Assoc (1978) 0.75
[Enalapril in the treatment of nephrogenic hypertension]. Vnitr Lek (1992) 0.75
[Modern diagnosis of energy and nitrogen balance in renal insufficiency]. Bratisl Lek Listy (1984) 0.75
[Prevention and therapy of atherosclerosis]. Bratisl Lek Listy (1996) 0.75
Enalapril inhibits growth and proliferation of various tissues in rat normotensive four-sixths kidney ablation nephropathy. Kidney Blood Press Res (2000) 0.75
Comparison of creatinine, hippuric acid, 5-hydroxyindoleacetic acid, serotonin, and pseudouridine concentrations in blood withdrawn from vein and arteriovenous fistula of uremic patients on maintenance hemodialysis. Artif Organs (1991) 0.75
[Bopindolol does not affect normal glucose and lipid metabolism in hypertensive patients]. Vnitr Lek (1989) 0.75
Metabolic actions of middle molecules. Artif Organs (1981) 0.75
[The informational value of creatinine determination]. Cas Lek Cesk (1986) 0.75
Membrane plasmapheresis raises the serum concentrations of pseudouridine. Int J Artif Organs (1991) 0.75
[The effect of acidification and alkalization on hippuran excretion]. Bratisl Lek Listy (1988) 0.75
[Prevention of progression in nephropathies]. Bratisl Lek Listy (1994) 0.75
[Treatment of renal hypertension]. Vnitr Lek (2000) 0.75
[Does therapeutic membrane plasmapheresis increase protein synthesis?]. Cas Lek Cesk (1992) 0.75
[Pharmacodynamics of angiotensin-converting enzyme inhibitors]. Vnitr Lek (1996) 0.75
[Relation between blood glucose and insulin in hemodialysis]. Bratisl Lek Listy (1993) 0.75
[The effect of dipyridamole on hippurate excretion in healthy volunteers and in patients with renal insufficiency]. Cas Lek Cesk (1991) 0.75
Inhibition of glucose uptake by 5-hydroxyindoleacetic acid in the isolated rat soleus muscle. Int Urol Nephrol (1996) 0.75
[Serum hippurate levels in patients with liver cirrhosis under basal conditions and after glucose administration]. Bratisl Lek Listy (1989) 0.75
[Pharmacokinetic aspects of therapy with methenamine hippurate]. Cas Lek Cesk (1987) 0.75
[The effect of hemoperfusion through activated charcoal on middle molecular substances in the plasma during a long-term dialysis program]. Cas Lek Cesk (1983) 0.75
[Nutritional status of patients before kidney transplantation]. Vnitr Lek (1984) 0.75
[Nephrologic manifestations of mitochondrial diseases]. Cas Lek Cesk (2000) 0.75
Isolation of an additional inhibitor of glucose utilization in renal insufficiency: pseudouridine. J Chromatogr (1990) 0.75
P-aminohippurate accumulation in kidney cortex slices: stimulation by dicarboxylates, amino acids and their oxoanalogues. Physiol Res (1991) 0.75
Pathogenesis of metabolic alterations in renal failure. Czech Med (1984) 0.75
[Nephrogenic metabolic acidosis]. Vnitr Lek (2003) 0.75
[Dermatoglyphics in gonadal dysgeneses of masculine and feminine phenotypes]. Cesk Pediatr (1970) 0.75
[New perspectives of treatment of osteoporosis with thiazides]. Vnitr Lek (1999) 0.75
[Lisinopril in the monotherapy of patients with essential hypertension: the effect of therapy on glucose and lipid metabolism]. Cas Lek Cesk (1993) 0.75
Effective long-term inhibition of thromboxane production but not of serotonin release in patients with coronary heart disease by 30 mg/d acetylsalicylic acid dosage. Prostaglandins Leukot Essent Fatty Acids (1998) 0.75
Dietary protein restriction in combination with angiotensin converting enzyme inhibitor improves insulin resistance in patients with chronic renal disease. Int Urol Nephrol (1997) 0.75
[The role of hippurate in kidney failure]. Ter Arkh (1992) 0.75
[Diuretics in the treatment of hypertension]. Vnitr Lek (1993) 0.75
Erythrocyte transport of middle molecular substances. Proc Eur Dial Transplant Assoc (1981) 0.75
The utilization of glucose in the brain slices during uraemia. Int Urol Nephrol (1974) 0.75
[Can the concentration of middle molecular substances in plasma contribute to the assessment of the adequacy of regular dialysis therapy?]. Cas Lek Cesk (1984) 0.75
Modulators and mediators of kidney disease progression: new targets of prevention and treatment. Bratisl Lek Listy (1997) 0.75
[Pefloxacin in the treatment of recurrent urinary tract infections]. Cas Lek Cesk (1990) 0.75
[Celiprolol improves glucose metabolism in essential hypertension]. Vnitr Lek (1998) 0.75
Can plasma concentration of middle molecules contribute to assessment of adequate dialysis treatment? Artif Organs (1986) 0.75
The prevalence of insulin resistance in essential hypertension. Cor Vasa (1993) 0.75
[Hippuran does not interfere with glucose metabolism and proximal tubule function in persons with normal renal function]. Cas Lek Cesk (1988) 0.75
[Insulin resistance in essential and nephrogenic hypertension]. Cas Lek Cesk (1994) 0.75
Folate levels determine effect of antioxidant supplementation on micronuclei in subjects with cardiovascular risk. Mutagenesis (2004) 0.75
[Clinico-pharmacologic possibilities of theophylline therapy]. Vnitr Lek (1987) 0.75
Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects. J Cardiovasc Pharmacol (2001) 0.75
Serum ferritin levels in subjects at high risk of atherosclerosis. Cent Eur J Public Health (2000) 0.75
[The primary importance of the kidneys in the development of essential hypertension]. Vnitr Lek (1993) 0.75
Middle molecular substances in acute renal failure. Int Urol Nephrol (1982) 0.75
[The role of thromboxane in the pathogenesis of nephropathies]. Vnitr Lek (1996) 0.75
[The effect of a single administration of magnesium sulfate on glucose tolerance and insulinemia in healthy volunteers]. Cas Lek Cesk (1991) 0.75
Serum ex vivo lipoprotein oxidizability in patients with ischemic heart disease supplemented with vitamin E. Physiol Res (2002) 0.75
[Metabolic changes in chronic kidney failure]. Bratisl Lek Listy (1978) 0.75
Inhibitor of renal gluconeogenesis (IGN): additional physiological modulator? Int J Biochem (1980) 0.75
Concentration of plasma middle molecular weight substances and clinical condition of patients undergoing short-time regular dialysis treatment. Artif Organs (1981) 0.75
[Improvement in glucose tolerance and insulin sensitivity after a single administration of tolbutamide in hypertensive patients]. Vnitr Lek (1991) 0.75
Effect of hippurate on tissue fatty acid metabolism. Physiol Bohemoslov (1990) 0.75
[Nitric oxide and the kidneys]. Vnitr Lek (2001) 0.75
Lipid peroxidation and nutrition. Physiol Res (2004) 0.75
Metabolic effects of enalapril in the treatment of essential hypertension. Cor Vasa (1992) 0.75
Influence of ACE inhibition on insulin resistance. Nephrol Dial Transplant (1995) 0.75
[Dependence of the level of glucose utilization inhibitor on creatinine clearance]. Cas Lek Cesk (1986) 0.75
[Diuretics in the treatment of hypertension]. Vnitr Lek (1996) 0.75